SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995; 153: 144450
  • 2
    Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organisation for Research and Treatment of Cancer, Medical Research Council randomised clinical trials for the prophylactic treatment of stage Ta-T1 bladder cancer. J Urol 1996; 156: 193441
  • 3
    Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and CIS). J Urol 1999; 162: 1697701
  • 4
    Bohle A, Brandau S. Immune mechanisms in Bacille Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 9649
  • 5
    Prout GR Jr, Griffin PP, Daly JJ. The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 1987; 138: 76670
  • 6
    Brosman SA. The use of BCG in the therapy of bladder carcinoma in situ. J Urol 1985; 134: 369
  • 7
    Herr HW, Pinsky CM, Whitmore WF Jr, Sogani PC, Oettgen HF, Melammed MR. Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder. J Urol 1986; 135: 2657
  • 8
    Kavoussi LR, Torrence RJ, Gillen DP et al. Results of 6 weekly intravesical BCG instillations on the treatment of superficial bladder tumours. J Urol 1988; 139: 93540
  • 9
    Reitsma DJ. Long-term effect of intravesical bacillus Calmette-Guerin (BCG) Tice strain on flat carcinoma in situ of the bladder. In DebruyneFMJ, Van Der MeijdenAPM eds, BCG in Superficial Bladder Cancer. New York: Wiley-Liss, 1989: 1717
  • 10
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomised trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 12049
  • 11
    Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997; 157: 16559
  • 12
    Takashi M, Shimoji T, Murase T et al. Intravesical Bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder. Int Urol Nephrol 1997; 29: 55763
  • 13
    Losa A, Hurle R, Lembo A. Low dose Bacillus Calmette-Guérin for carcinoma in situ of the bladder: Long-term results. J Urol 2000; 163: 6872
  • 14
    Rintala E, Jauhiainen K, Alfthan O, Hansson E et al. Intravesical chemotherapy (Mitomycin C) versus immunotherapy (bacille Calmette-Guerin) in superficial bladder cancer. Eur Urol 1991; 20: 1925
  • 15
    Melekos MD, Chionis HS, Parnychianakis GS, Bauaher HH. Intravesical 4-epdoxorubicin (epirubicin) versus bacillus calmette-guerin. Cancer 1993; 5: 174955
  • 16
    Lamm DL, Blumenstein BA, Crawford ED et al. Randomised intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1995; 1: 11926
  • 17
    Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, Van Der Meijden AP. A randomised study of intravesical mitomycin C, bacillus calmette-guerin tice and bacillus calmette-guerin RIVM treatment of the bladder. J Urol 1995; 153: 92933
  • 18
    Lundholm C, Norlen BJ, Ekman P, Jahnson S et al. A randomised prospective study comparing long-term intravesical instillation of mitomycin C and bacillus calmette-guerin in patients with superficial bladder carcinoma. J Urol 1996; 156: 3726
  • 19
    Krege S, Giani G, Meyer R, Otto T, Ruben H. and participating clinics. A randomised multicentre trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus bacillus calmette-guerin. J Urol 1996; 156: 9626
  • 20
    Witjes JA, Van Der Meijden AP, Collette L et al. Long-term follow-up of an EORTC randomised prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. Urology 1998; 52: 40310
  • 21
    Van Der Meijden AP, Brausi M, Zambon V et al. Intravesical instillation of epirubicin, Bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organisation for Research and Treatment of Cancer Genito-urinary Group randomised phase III trial. J Urol 2001; 166: 47681
  • 22
    Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder. Am J Clin Oncol 2003; 26: 4027
  • 23
    Sylvester RJ, Van Der Meijden AP, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 24
    Au JL, Badalament RA, Wientjes MG et al. Methods to improve efficacy of intravesical Mitomycin C. Results of a randomized phase III trial. J Natl Cancer Inst 2001; 93: 597604
  • 25
    Herr HW, Badalament VP, Oettgen RA et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 14505
  • 26
    Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose baccilus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol 1991; 146: 325
  • 27
    Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158: 627
  • 28
    Bohle A, Jocham D, Bock PR. Intravesical Bacillus Calmette-Guerin versus Mitomycin C for superficial bladder cancer. A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 905
  • 29
    Bohle A, Bock PR. Intravesical Bacille Calmette-Guerin versus Mitomycin C in superficial bladder cancer. formal meta-analysis of comparative studies on tumour progression. Urology 2004; 63: 6827
  • 30
    Griffiths GO, Parmar MK. Intravesical Bacille Calmette-Guerin versus Mitomycin C in superficial bladder cancer. formal meta-analysis of comparative studies on tumour progression – Editorial Comment. Urology 2004; 63: 6867
  • 31
    Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical Bacillus Calmette-Guerin versus Mitomycin C for Ta and T1 bladder cancer (Cochrane Review). In The Cochrane Library. Issue 4. Chichester, UK: John Wiley & Sons, Ltd, 2003